Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Sofant and Inmarsat announce joint development

24 May 2023 07:00

RNS Number : 4074A
NetScientific PLC
24 May 2023
 

Reach: 24 May 2023

NetScientific plc

("NetScientific" or the "Company")

Sofant Technologies and Inmarsat Government to develop Phased Array Antenna for Aircraft

NetScientific Plc (AIM: NSCI), investment and commercialisation group with an international portfolio of innovative life science, sustainability and technology companies, reports that its portfolio company, Sofant Technologies ("Sofant"), a leading innovator in advanced antenna technologies, and Inmarsat Government ("Inmarsat"), the leading provider of secure, global, mission-critical telecommunications to the US Government, have today announced a joint development aimed at revolutionising the communication capabilities of aircraft.

Together, Sofant and Inmarsat will collaborate on a state-of-the-art phased array antenna designed to enhance connectivity, reliability, and performance in airborne operations.

The collaboration will combine their respective expertise to develop an innovative solution that addresses the Government airborne users' growing demand for efficient, low-profile communication systems.

The new phased array antenna will leverage Sofant's core technology to produce a compact, lightweight, and low-power terminal, which will enable reliable, seamless high-speed global coverage on a wider range of aircraft through Inmarsat's Global Xpress (GX) network, the world's first and only high-throughput commercial wideband network available worldwide. This includes seamless switching on the GX commercial network's global service beams and Inmarsat's high-capacity, global military Ka-band (Mil Ka) network's steerable beams.

David Wither, CEO, Sofant Technologies, said:

"We are thrilled to partner with Inmarsat Government on this development program. By leveraging our leading-edge antenna technology, we aim to deliver a transformative solution that will redefine communication capabilities for airborne platforms. This collaboration aligns with our vision of revolutionizing connectivity in the aerospace industry and beyond. We are confident that our joint efforts will yield exceptional results."

Steve Gizinski, President, Inmarsat Government, said:

"We are dedicated to providing cutting-edge communication solutions that empower our customers to excel in their missions. Collaborating with Sofant Technologies allows us to push the boundaries of innovation further, and together, we will develop a phased array antenna that sets new industry standards. This collaboration represents a significant step forward in meeting the Government's growing demand for secure and reliable connectivity worldwide."

Dr Ilian Iliev, CEO of NetScientific, added:

"We gained exposure to the Sofant investment through our acquisition of EMV Capital and its portfolio, and since then NetScientific has supported investments through our capital light investment approach, combining direct and advised stakes. A key feature of our deep tech investment model is to encourage portfolio companies to work closely with global OEMs as a capital efficient way of growth, and to internationalise early. Hence, we are delighted with today's announcement, which is a significant milestone for Sofant. The development collaboration between Inmarsat and Sofant underscores their commitment to driving advancements in airborne communication technology."

-Ends- 

For more information, please contact:

 

NetScientific

Ilian Iliev, CEO Via Belvedere Communications

 

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel / Enzo Aliaj +44 (0)20 7220 1666

 

Belvedere Communications

John West / Llew Angus +44 (0) 203 008 6867

Email: nsci@belvederepr.com

 

About NetScientific

NetScientific plc (AIM: NSCI) is an investment and commercialisation group with an international portfolio of innovative life science, sustainability and technology companies.

NetScientific identifies, invests in, and builds high growth companies in the UK and internationally. The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.

NetScientific differentiates itself by employing a capital-light investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.

NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.

www.netscientific.net

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRASEUFMDEDSEFI
Date   Source Headline
30th Mar 20233:51 pmRNSPDS Update
28th Mar 20233:50 pmRNSPDS Business Update and 2022 Financial Results
28th Feb 20237:00 amRNSRelated party loan to ProAxsis Limited
27th Feb 20233:28 pmRNSPDS completes FDA meeting for triple combination
10th Feb 20232:05 pmRNSSecond Price Monitoring Extn
10th Feb 20232:00 pmRNSPrice Monitoring Extension
10th Feb 202311:05 amRNSSecond Price Monitoring Extn
10th Feb 202311:00 amRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSBoard Change
3rd Jan 20231:31 pmRNSPDS Announces Exclusive Global License Agreement
28th Dec 20223:05 pmRNSPDS Biotech: Median Overall Survival announcement
16th Dec 20227:00 amRNSPDS: HPV16 Head and Neck Cancer announcement
12th Dec 20222:00 pmRNSBoard Changes; Options; Co-Investment Agreement
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn
14th Nov 20222:00 pmRNSPrice Monitoring Extension
9th Nov 20227:00 amRNSBoard Change
7th Nov 20223:40 pmRNSPDS reports presentation of data at cancer society
20th Oct 20227:00 amRNSEMV Capital secures investment in Ventive
11th Oct 20224:00 pmRNSPDS Update
3rd Oct 20221:56 pmRNSPDS completes End-of-Phase 2 meeting with FDA
30th Sep 20227:00 amRNSHalf-year Report
25th Aug 20227:00 amRNSPDS Completes $35 Million Financing Agreement
16th Aug 20227:00 amRNSAcquisition of 30% Vortex stake & new Vortex CEO
8th Aug 20224:45 pmRNSPDS Reports Q2 2022 Results & Business Update
29th Jun 20222:05 pmRNSResult of AGM
28th Jun 20229:15 amRNSHolding(s) in Company
27th Jun 20228:30 amRNSHolding(s) in Company
27th Jun 20228:30 amRNSDirector/PDMR Shareholding
22nd Jun 20227:00 amRNSResult of Placing and Total Voting Rights
21st Jun 20224:41 pmRNSProposed Placing to raise at least £1.5 million
17th Jun 202212:00 pmRNSNetScientific to increase Q-Bot stake to 23.7%
15th Jun 20227:00 amRNSQ-Bot secures £1.6m of investment to fund growth
7th Jun 202211:07 amRNSNotice of AGM and Annual Report & Accounts
6th Jun 20227:00 amRNSPDS Granted FDA Fast Track Designation for PDS0101
27th May 20222:39 pmRNSPDS Biotech - new data for ongoing clinical trials
19th May 20227:00 amRNSGeneral Counsel Strategic Hire & Grant of Options
16th May 20227:00 amRNSProAxsis Update
12th May 20227:00 amRNSFinal Results
11th May 20223:46 pmRNSPDS Reports Q1 2022 Results & Business Update
9th May 20227:00 amRNSNotice of Results & Investor Presentation
6th May 20227:00 amRNSAcquisition of 30% of Vortex Biotech Holdings
25th Apr 20222:05 pmRNSSecond Price Monitoring Extn
25th Apr 20222:00 pmRNSPrice Monitoring Extension
25th Apr 202211:05 amRNSSecond Price Monitoring Extn
25th Apr 202211:00 amRNSPrice Monitoring Extension
31st Mar 20221:24 pmRNSPDS Provides Business Update & Full-Year Results
4th Mar 20227:30 amRNSPublication of Shareholder Newsletter
24th Feb 20224:45 pmRNSPDS Announces Preliminary Safety Data on PDS0101

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.